<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00210119</url>
  </required_header>
  <id_info>
    <org_study_id>IB2005-25</org_study_id>
    <secondary_id>AFR22</secondary_id>
    <nct_id>NCT00210119</nct_id>
  </id_info>
  <brief_title>Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response</brief_title>
  <acronym>AFR22</acronym>
  <official_title>Multicentric Phase II Study to Evaluate Feasibility and Efficacy of Association of Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response After One Year of Imatinib Mesylate Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Bergonié</source>
  <brief_summary>
    <textblock>
      Imatinib mesylate is standard treatment of Chronic myeloid leukaemia, complete cytogenetic
      response is obtained in most of cases but molecular response concerned only a small part of
      the patients. To increase molecular response ratio we decided to increase imatinib dose to
      limited resistance to this drug and to add zoledronate for it anti tumoral activity to
      increase anti leukemic effect. We plan to accrue 37 patients in 5 centers. We will analyse
      molecular expression of BCR-ABL transcript after 6 months of treatment, safety, duration of
      response, VEGF expression and LTgd production.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate efficacy on molecular response after 6 months of association treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety, efficacy after 3 months, antitumoral activity via VEGF and LTgd, period duration of molecular response</measure>
  </secondary_outcome>
  <enrollment type="Actual">17</enrollment>
  <condition>Myeloid Leukemia, Chronic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib mesylate and zoledronic acid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion criteria: at registration· Chronic myeloid leukaemia Ph+ confirmed by
             cytogenetic analysis or BCR-ABL translocation by molecular biology· Chronic
             phase:-&lt;15% blast cells in blood and 5% in bone marrow-&lt;30% blast cells+promyelocyte
             cells in blood and bone marrow-&lt;20% basophils in blood-&gt;100.000 platelets· Without
             extra medullar attempt excepted hepatosplenomagalia· First line of treatment· Biology
             and biochemistry with normal levels· Male or female&gt;18 years old· Signed written
             consent· ECOG&lt;3At inclusion· Chronic myeloid leukaemia with cytogenetic response
             without molecular response after one year of treatment by imatinib and BCR-ABL
             transcript detected by RT-PCR

        Exclusion Criteria:

          -  · Other cancer excepted basocellular or cervix carcinoma · Major surgery in last 2
             weeks previous inclusion· Women who are pregnant or breastfeeding (are unable to use
             an acceptable method to avoid pregnancy of his partner for the entire study period)·
             Dementia or altered mental status that would prohibit the understanding or rendering
             of informed consent · Abnormal renal function with creatinine clearance &lt; 30 ml/
             minuteAccording to Cockcroft-Gault : CrCl= [[140-age (years)] x weight (kg)]/ [72 x
             serum creatinine (mg/dL)] {x 0.85 for women}· Chronic myeloid leukaemia in acute phase
             or in pass to be in acute phase · Treatment with bisphosphonates in last 6 months
             previous inclusion · Intolerance to bisphosphonates: hypersensitivity, on course
             dental problem, including tooth or mandibular infection; dental traumatism or recent
             diagnosis or previous mandibular osteonecrosis, or dental extraction with
             cicatrisation delay or necessity to set bone evidence · Mandibular surgery in last 6
             weeks or planned in the future during treatment (tooth extraction)· Serious
             uncontrolled medical disorder or active infection that would impair the ability of the
             subject to receive protocol therapy: diabetes, thyroid pathology, neuropsychiatric
             illness, myocardial infarction or congestive heart failure grade 3-4 according to &quot;
             New York Heart association&quot;· History of psychiatric or depressive pathology · HIV
             positivity known · Inclusion in other study investigating antineoplastic molecule in
             last 30 days previous inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josy REIFFERS, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié - Centre Régional de Luttre Contre le Cancer de Bordeaux et du Sud Ouest</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Archet</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>July 25, 2013</last_update_submitted>
  <last_update_submitted_qc>July 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2013</last_update_posted>
  <keyword>Chronic myeloid leukemia</keyword>
  <keyword>imatinib mesylate</keyword>
  <keyword>zoledronate</keyword>
  <keyword>molecular response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

